S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Triple Negative Breast Cancer
-
Age: Between 18 years - 90 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Patients must have histologically confirmed ER-, PR- and HER2-negative (triple-negative, TNBC) with residual invasive breast cancer (positive lymph nodes or at least 1 cm invasive cancer in the breast)
2. Patients must not have metastatic disease
3. Patients must have had neoadjuvant chemotherapy followed by surgery
4. Additional chemotherapy and/or radiation is allowed after surgery, but enrollment must occur shortly after
You may not be eligible for this study if the following are true:
-
1. Patients with a history of (non-infectious) pneumonitis that required steroid or evidence of active pneumonitis
2. Patients with certain autoimmune diseases
3. Patients who have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.